J2351 HCPCS Level II code: Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
J2351 is the HCPCS code for “Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
Short description: Inj ocrelizumab 1mg hya-ocsq
HCPCS · United States
Medicare details
The indicators CMS publishes with J2351 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Apr 1, 2025
Where J2351 sits
- 1J codesDrugs administered other than orally
- 2Active code J2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J2351 mean?
J2351 is the HCPCS code for “Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J2351?
CMS lists J2351’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J2351
All J codesJ2323Injection, natalizumab, 1 mgJ2325Injection, nesiritide, 0.1 mgJ2326Injection, nusinersen, 0.1 mgJ2327Injection, risankizumab-rzaa, intravenous, 1 mgJ2329Injection, ublituximab-xiiy, 1mgJ2350Injection, ocrelizumab, 1 mgJ2353Injection, octreotide, depot form for intramuscular injection, 1 mgJ2354Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcgJ2355Injection, oprelvekin, 5 mgJ2356Injection, tezepelumab-ekko, 1 mgJ2357Injection, omalizumab, 5 mgJ2358Injection, olanzapine, long-acting, 1 mg